Argent BioPharma Limited
RGTLF
$0.0599
$0.011423.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -77.90% | -75.10% | -74.35% | -73.95% | -73.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.90% | -75.10% | -74.35% | -73.95% | -73.55% |
| Cost of Revenue | -41.41% | -41.80% | -42.73% | -60.67% | -70.24% |
| Gross Profit | -295.42% | -144.04% | -122.12% | -104.38% | -84.09% |
| SG&A Expenses | 41.07% | 24.84% | 8.84% | -8.25% | -22.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 14.78% | -134.76% | -874.37% | -188.06% | -142.74% |
| Total Operating Expenses | 21.29% | 7.04% | -6.40% | -19.49% | -30.04% |
| Operating Income | -30.52% | -20.12% | -8.71% | 5.45% | 17.40% |
| Income Before Tax | -30.50% | -3.97% | 19.04% | 25.81% | 31.03% |
| Income Tax Expenses | -- | -- | -- | -100.00% | -100.00% |
| Earnings from Continuing Operations | -30.50% | -3.97% | 19.04% | 25.81% | 31.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -99.78% | -95.97% | -94.34% | -80.22% | -70.48% |
| Net Income | -31.55% | -5.15% | 17.92% | 24.88% | 30.28% |
| EBIT | -30.52% | -20.12% | -8.71% | 5.45% | 17.40% |
| EBITDA | -31.91% | -18.96% | -5.56% | 9.00% | 21.46% |
| EPS Basic | 86.85% | 91.03% | 93.09% | 76.73% | 63.30% |
| Normalized Basic EPS | 87.75% | 89.38% | 90.38% | 70.94% | 53.43% |
| EPS Diluted | 86.97% | 91.08% | 93.12% | 76.59% | 62.96% |
| Normalized Diluted EPS | 87.75% | 89.38% | 90.38% | 70.94% | 53.43% |
| Average Basic Shares Outstanding | 284.88% | 443.86% | 1,155.85% | 794.37% | 394.91% |
| Average Diluted Shares Outstanding | 284.88% | 443.86% | 1,155.85% | 794.37% | 394.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |